{"id":"ocrelizumab-iv","safety":{"commonSideEffects":[{"rate":"approximately 40%","effect":"Infusion-related reactions"},{"rate":"approximately 25%","effect":"Upper respiratory tract infections"},{"rate":"approximately 15%","effect":"Lower respiratory tract infections"},{"rate":"approximately 20%","effect":"Nasopharyngitis"},{"rate":"approximately 10%","effect":"Headache"},{"rate":"approximately 2-3%","effect":"Immunosuppression/serious infections"}]},"_chembl":{"chemblId":"CHEMBL2108041","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ocrelizumab targets CD20, a surface antigen expressed on B cells, leading to B cell depletion through antibody-dependent cellular cytotoxicity (ADCC) and direct induction of apoptosis. By eliminating B cells, the drug reduces the production of autoimmune antibodies and pro-inflammatory cytokines, thereby suppressing the autoimmune response underlying multiple sclerosis and other B cell-driven conditions.","oneSentence":"Ocrelizumab is a monoclonal antibody that depletes B cells by binding to CD20, reducing autoimmune-mediated inflammation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:23:52.845Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing-remitting multiple sclerosis (RRMS)"},{"name":"Primary progressive multiple sclerosis (PPMS)"}]},"trialDetails":[{"nctId":"NCT04544449","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-10-26","conditions":"Multiple Sclerosis, Primary Progressive","enrollment":985},{"nctId":"NCT05285891","phase":"PHASE4","title":"Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-01-12","conditions":"Multiple Sclerosis","enrollment":123},{"nctId":"NCT07483450","phase":"PHASE4","title":"A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-07-04","conditions":"Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis","enrollment":60},{"nctId":"NCT06700343","phase":"PHASE3","title":"Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)","status":"RECRUITING","sponsor":"Amgen","startDate":"2025-01-13","conditions":"Relapsing-remitting Multiple Sclerosis (RRMS)","enrollment":444},{"nctId":"NCT04035005","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2019-08-12","conditions":"Multiple Sclerosis, Primary Progressive","enrollment":1013},{"nctId":"NCT06675955","phase":"PHASE3","title":"An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2024-12-13","conditions":"Multiple Sclerosis","enrollment":500},{"nctId":"NCT04544436","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-11-26","conditions":"Multiple Sclerosis","enrollment":864},{"nctId":"NCT07389590","phase":"PHASE4","title":"Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis","status":"NOT_YET_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2026-02","conditions":"Multiple Sclerosis","enrollment":50},{"nctId":"NCT04377555","phase":"PHASE4","title":"Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2020-07-30","conditions":"Multiple Sclerosis, Relapsing","enrollment":179},{"nctId":"NCT03523858","phase":"PHASE3","title":"A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2018-05-28","conditions":"Progressive Multiple Sclerosis (PMS)","enrollment":927},{"nctId":"NCT05123703","phase":"PHASE3","title":"A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-05-19","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":188},{"nctId":"NCT04466150","phase":"PHASE4","title":"Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2020-08-30","conditions":"Relapsing Multiple Sclerosis, Clinically Isolated Syndrome","enrollment":30},{"nctId":"NCT04998851","phase":"PHASE4","title":"A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2021-09-16","conditions":"Multiple Sclerosis, Clinically Isolated Syndrome","enrollment":26},{"nctId":"NCT04548999","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-12-03","conditions":"Multiple Sclerosis","enrollment":769},{"nctId":"NCT03599245","phase":"PHASE3","title":"This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-07-12","conditions":"Multiple Sclerosis","enrollment":1055},{"nctId":"NCT03500328","phase":"NA","title":"Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2018-05-02","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":900},{"nctId":"NCT04998812","phase":"PHASE4","title":"A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2022-04-13","conditions":"Multiple Sclerosis, Clinically Isolated Syndrome","enrollment":70},{"nctId":"NCT05232825","phase":"PHASE3","title":"A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2022-05-03","conditions":"Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis","enrollment":236},{"nctId":"NCT03972306","phase":"PHASE1","title":"A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-08-12","conditions":"Multiple Sclerosis (MS)","enrollment":134},{"nctId":"NCT04578639","phase":"PHASE3","title":"Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Haukeland University Hospital","startDate":"2020-11-02","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":214},{"nctId":"NCT03477500","phase":"PHASE3","title":"Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Haukeland University Hospital","startDate":"2018-03-21","conditions":"Multiple Sclerosis","enrollment":100},{"nctId":"NCT04848493","phase":"","title":"National Project on Vaccines, COVID-19 and Frail Patients","status":"COMPLETED","sponsor":"Azienda USL Reggio Emilia - IRCCS","startDate":"2021-04-19","conditions":"COVID-19, Solid Tumor, Hematologic Diseases","enrollment":747},{"nctId":"NCT03344094","phase":"","title":"Mechanism of Action of Ocrelizumab in Multiple Sclerosis","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2018-02-23","conditions":"Multiple Sclerosis, Immune System Diseases","enrollment":30},{"nctId":"NCT03085810","phase":"PHASE3","title":"Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2017-03-24","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":1225},{"nctId":"NCT00676715","phase":"PHASE2","title":"A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2008-07-17","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":220},{"nctId":"NCT06127095","phase":"","title":"A Study to Assess New Participant's Perspectives Beyond Clinical Efficacy of Monoclonal Antibody-Based Relapsing Remitting Multiple Sclerosis (RRMS) Treatments","status":"COMPLETED","sponsor":"Biogen","startDate":"2023-11-24","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":474},{"nctId":"NCT06711354","phase":"","title":"B-cell Depletion in Offspring to Women With MS Under Immunomodulatory Treatment","status":"NOT_YET_RECRUITING","sponsor":"Region Stockholm","startDate":"2025-06","conditions":"Multiple Sclerosis, B-Cell Deficiency, Offspring, Adult","enrollment":111},{"nctId":"NCT05081700","phase":"","title":"A Systems Approach to Understanding Disease Processes in Multiple Sclerosis","status":"COMPLETED","sponsor":"Providence Health & Services","startDate":"2020-05-11","conditions":"Multiple Sclerosis","enrollment":14},{"nctId":"NCT02688985","phase":"PHASE3","title":"Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2016-04-29","conditions":"Relapsing Multiple Sclerorsis, Multiple Sclerosis, Primary Progressive","enrollment":131},{"nctId":"NCT05906992","phase":"PHASE3","title":"A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis","status":"RECRUITING","sponsor":"Celltrion","startDate":"2024-01-11","conditions":"Relapsing-remitting Multiple Sclerosis","enrollment":512},{"nctId":"NCT02545868","phase":"PHASE3","title":"A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-10-27","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":102},{"nctId":"NCT01412333","phase":"PHASE3","title":"A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-09-20","conditions":"Relapsing Multiple Sclerosis","enrollment":835},{"nctId":"NCT01247324","phase":"PHASE3","title":"A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-08-31","conditions":"Relapsing Multiple Sclerosis","enrollment":821},{"nctId":"NCT03971487","phase":"PHASE1, PHASE2","title":"Ocrelizumab for Psychosis by Autoimmunity","status":"UNKNOWN","sponsor":"The Methodist Hospital Research Institute","startDate":"2019-10-01","conditions":"Schizo-Affective Type of Psychosis, Schizophrenia","enrollment":40},{"nctId":"NCT01194570","phase":"PHASE3","title":"A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-03-02","conditions":"Multiple Sclerosis, Primary Progressive","enrollment":735},{"nctId":"NCT04189588","phase":"PHASE2","title":"Phase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine","status":"COMPLETED","sponsor":"TerSera Therapeutics LLC","startDate":"2020-03-25","conditions":"Oncology Patients Receiving Chemotherapy","enrollment":34},{"nctId":"NCT03691077","phase":"PHASE3","title":"Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-11-11","conditions":"Multiple Sclerosis, Relapse, Primary Progressive Multiple Sclerosis","enrollment":51},{"nctId":"NCT04676555","phase":"","title":"Time and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple Sclerosis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-05-11","conditions":"Relapsing Forms of Multiple Sclerosis","enrollment":2},{"nctId":"NCT04966338","phase":"PHASE3","title":"Efficacy and Safety of Xacrel® (Ocrelizumab) in Participants With Relapsing Remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"Cinnagen","startDate":"2019-08-19","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":170},{"nctId":"NCT02861014","phase":"PHASE3","title":"A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-09-09","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":681},{"nctId":"NCT03589105","phase":"PHASE4","title":"A Study to Provide Complementary Efficacy, Safety and Patient Reported Outcomes Data in Participants With Active Relapsing Forms of Multiple Sclerosis (MS) in a Pragmatic Setting","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-08-06","conditions":"Multiple Sclerosis","enrollment":423},{"nctId":"NCT02980042","phase":"PHASE3","title":"Safety of Switching From Rituximab to Ocrelizumab in MS Patients","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2017-01-01","conditions":"Multiple Sclerosis","enrollment":200},{"nctId":"NCT00626197","phase":"PHASE3","title":"A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG)","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2008-02-15","conditions":"Lupus Nephritis, Systemic Lupus Erythematosus","enrollment":381},{"nctId":"NCT00673920","phase":"PHASE3","title":"A Study to Evaluate Ocrelizumab Compared With Placebo in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2008-04-24","conditions":"Rheumatoid Arthritis","enrollment":314},{"nctId":"NCT00406419","phase":"PHASE3","title":"A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE)","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2006-12-27","conditions":"Rheumatoid Arthritis","enrollment":1015},{"nctId":"NCT00808210","phase":"PHASE2","title":"A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2009-03-05","conditions":"Rheumatoid Arthritis","enrollment":28},{"nctId":"NCT02637856","phase":"PHASE3","title":"A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2016-02-11","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":608},{"nctId":"NCT00476996","phase":"PHASE3","title":"A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2007-05-15","conditions":"Rheumatoid Arthritis","enrollment":836},{"nctId":"NCT02723071","phase":"PHASE1, PHASE2","title":"A Study of Ocrelizumab in Participants With Follicular Non-Hodgkin's Lymphoma (NHL)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-05","conditions":"Non-Hodgkin's Lymphoma","enrollment":48},{"nctId":"NCT02720120","phase":"PHASE1, PHASE2","title":"A Study of Ocrelizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA)","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2005-10","conditions":"Rheumatoid Arthritis","enrollment":175}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":46,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["RO4964913"],"phase":"phase_3","status":"active","brandName":"Ocrelizumab IV","genericName":"Ocrelizumab IV","companyName":"Hoffmann-La Roche","companyId":"roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ocrelizumab IV is an antibody that binds to the B-lymphocyte antigen CD20, classified as a BINDING AGENT. It is used to treat conditions such as Relapsing-Remitting Multiple Sclerosis, Primary Progressive Multiple Sclerosis, and Rheumatoid Arthritis, among others.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}